Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60121 Ancona, Italy.
Toxins (Basel). 2023 Feb 11;15(2):147. doi: 10.3390/toxins15020147.
Botulinum toxin type B (BoNT-B), known as Myobloc in the United States and as Neurobloc in Europe, is a new therapeutically available serotype among the botulinum toxin family. During the last years several data have been reported in literature investigating its efficacy and safety, as well as defining the dosing and application regiments of BoNT-B in the treatment of hyperhidrosis. Moreover, recent studies have been examining its safety profile, which may be different from those known about BoNT-A. The aim of this review is to provide information about what is currently known about BoNT-B in regards to the treatment of focal hyperhidrosis.
肉毒杆菌毒素 B 型（BoNT-B），在美国被称为 Myobloc，在欧洲被称为 Neurobloc，是肉毒毒素家族中一种新的可治疗的血清型。在过去的几年中，文献中报道了多项关于其疗效和安全性的研究，以及确定 BoNT-B 治疗多汗症的剂量和应用方案。此外，最近的研究还在检查其安全性概况，这可能与已知的 BoNT-A 不同。本综述的目的是提供关于 BoNT-B 在治疗局限性多汗症方面的最新信息。
